Pattern Bioscience

Pattern Bioscience is a private, pre-revenue diagnostics company founded in 2017 and headquartered in Austin, Texas. It is developing a disruptive platform that applies single-cell analysis to directly from patient samples, bypassing lengthy culture steps to provide phenotypic ID/AST results in hours. Led by a seasoned CEO with deep clinical microbiology expertise and a founder-CTO with a diagnostics engineering background, the company is targeting the critical need to reduce inappropriate antibiotic use, which drives antimicrobial resistance (AMR). Its technology has been recognized with awards like the 2023 Disruptive Technology Award.

Single-cell microbiology platform that isolates individual bacterial cells from clinical samples and decodes their metabolic patterns to perform rapid phenotypic identification and antibiotic susceptibility testing (ID/AST).

Pattern competes in the rapid diagnostic space against companies using molecular (genotypic) methods (e.g., BioFire, Cepheid) and other emerging phenotypic technologies. Its key differentiation is offering gold-standard phenotypic results at a speed approaching genotypic tests, but it must prove this in practice to displace established automated culture and ID/AST systems.